跳至主要内容
临床试验/NCT01847248
NCT01847248已完成不适用

HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

Changhai Hospital1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
118
试验地点
1
主要终点
28-day mortality

研究概览

简要总结

  • Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis.
  • HSPA12B is primarily located in endothelial cells and detectable during sepsis.
  • The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients
  • Patients meet the diagnostic criteria according to the grouping

排除标准

  • patients without informed consent
  • patients who were undergoing continuous renal replacement therapy before sampling
  • patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on

结局指标

主要结局

28-day mortality

时间窗: 28 days

mortality within 28 days after recruitment.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jia-feng Wang

Dr.

Changhai Hospital

研究点 (1)

Loading locations...

相似试验